| 2020年版和2011年版中国药物经济学评价指南比较分析 |
| |
| 引用本文： | 王李婷,彭六保,彭烨,李斯妮,万小敏,曾小慧,谭重庆. 2020年版和2011年版中国药物经济学评价指南比较分析[J]. 中国药物经济学, 2021, 0(3): 5-8,15 |
| |
| 作者姓名： | 王李婷 彭六保 彭烨 李斯妮 万小敏 曾小慧 谭重庆 |
| |
| 作者单位： | 中南大学湘雅二医院药学部;中南大学湘雅二医院护理部;中南大学湘雅二医院PET-CT |
| |
| 基金项目： | 科卫联合基金项目(2020JJ8046)。 |
| |
| 摘 要： | 通过比较2020年版和2011年版中国药物经济学评价指南,分析两版指南的差异,并对更新内容进行解读,为药物经济学评价报告提供最新依据.比较两本指南,对更新要点进行总结和分析.2020年版药物经济学指南与2011年版药物经济学指南比较,有较多更新.详细说明了干预措施和对照选择;将成本测量和成本估值分开进行阐述;贴现分析单...
|
| 关 键 词： | 评价 指南 药物经济学 |
Comparative Analysis Between 2020 Version and 2011 Version on China Guidelines for Pharmacoeconomic Evaluation |
| |
| WANG Li-Ting,PENG Liu-Bao,PENG Ye,LI Si-Ni,WAN Xiao-Min,ZENG Xiao-Hui,TAN Chong-Qing. Comparative Analysis Between 2020 Version and 2011 Version on China Guidelines for Pharmacoeconomic Evaluation[J]. China Journal of Pharmaceutical Economics, 2021, 0(3): 5-8,15 |
| |
| Authors: | WANG Li-Ting PENG Liu-Bao PENG Ye LI Si-Ni WAN Xiao-Min ZENG Xiao-Hui TAN Chong-Qing |
| |
| Affiliation: | (Pharmacy Department,Xiangya Second Hospital,Central South University,Changsha 410011,China;Nursing Department,Xiangya Second Hospital,Central South University,Changsha 410011,China;PET-CT,Xiangya Second Hospital,Central South University,Changsha 410011,China) |
| |
| Abstract: | By comparing the 2020 Edition and 2011 Edition of China Pharmacoeconomics Evaluation Guidelines, the differences between the 2 editions were found, and the updated contents were interpreted to provide the latest basis for pharmacoeconomics evaluation report. A total of 2 guides were compared, the update points were summarized and analyzed. There are more updates in pharmacoeconomics guidelines 2020 compared with pharmacoeconomics guidelines 2011. This paper described the intervention measures and control options in detail;described the cost measurement and cost valuation separately;listed discount analysis as a separate part;updated health output, model analysis and budget impact analysis;recommended the use of cost utility analysis;and integrated the latest international research progress and analyzed the practical problems in China. Through the interpretation of the updated part of China pharmacoeconomics evaluation guide 2020, it is suggested that the 2020 Guidelines for Gharmacoeconomic Evaluation should be widely referenced and used to provide reference for further improving the quality of pharmacoeconomics research reports in the future. |
| |
| Keywords: | Evaluation Guideline Pharmacoeconomic |
| 本文献已被 维普 等数据库收录！ |
|
